After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro ...

Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced ...

CMO Dietmar Berger leads Gilead's R&D efforts with 54 clinical programs, anticipating Sunlenca's HIV PrEP launch & touting no ...

Chinese API manufacturers Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical have been placed on US import alert ...

Spring­Works Ther­a­peu­tics, a biotech po­ten­tial­ly on the verge of be­ing ac­quired, won its sec­ond FDA ap­proval. Get ...

FDA grants priority review for Biohaven's troriluzole for spinocerebellar ataxia after real-world data submission. Decision ...

Travere Therapeutics said Tuesday it plans to ask the FDA for approval of its kidney drug Filspari in a rare condition known ...

Health acquires Caraway Health, merging pediatric urgent care with Gen Z virtual care. The deal is another tying together two ...

A federal court in Massachusetts temporarily blocked the Trump administration’s new cap on indirect cost reimbursements for ...

Major pharma firms like Eli Lilly, GSK, Merck, Regeneron and Sanofi announce $35B+ in share buybacks since December, ...

Inventiva is trimming its pipeline and enacting layoffs in an effort to get its lead MASH drug approved, the company ...

Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and ...